Natera, Inc.
NTRAHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, Natera, Inc. (NTRA) is listed under Diagnostics & Research. At a $31.34B market cap, Natera, Inc. ranks as a large-cap company within healthcare. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Market Cap
$31.34B
Beta
1.57
P/E (TTM)
—
P/E (Fwd)
-578.66
EPS (TTM)
$-1.62
EPS (Fwd)
$-0.38
ROE
-15.0%
ROA
-9.1%
Cash
$1.09B
Total Debt
$240.1M
Free CF
$136.9M
52W Change
36.6%
Annual Financials
Cash vs Debt
Natera, Inc. holds $1.09B in cash against $240.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $136.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -15.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $820.2M (2022) to $2.31B (2025), reflecting a 181% increase over the period.
With a beta above 1.5, NTRA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, NTRA has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Natera, Inc.'s trajectory.